Stockscreener 앱 받기
18.05
0.36%
0.065
시장 영업 전:
17.84
-0.205
-1.14%
전일 마감가:
$17.98
열려 있는:
$18.18
하루 거래량:
51,426
Relative Volume:
2.08
시가총액:
$6.04B
수익:
$417.75M
순이익/손실:
$32.27M
주가수익비율:
185.08
EPS:
0.0975
순현금흐름:
-
1주 성능:
-13.78%
1개월 성능:
-1.72%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$17.92
$18.68
1주일 범위
$17.60
$20.57
52주 변동 폭
$14.01
$30.36
Telix Pharmaceuticals Ltd Adr Stock (TLX) Company Profile
TLX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TLX
Telix Pharmaceuticals Ltd Adr
|
18.05 | 6.04B | 417.75M | 32.27M | 0 | 0.0975 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.11B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 74.87B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.83B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 26.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Telix Pharmaceuticals Ltd Adr Stock (TLX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-15 | 개시 | UBS | Buy |
Telix Pharmaceuticals Ltd Adr 주식(TLX)의 최신 뉴스
Can Telix's Cancer Therapies Transform Urology Treatment? Top Oncologists Weigh In - StockTitan
Could This New Kidney Cancer Imaging Tool Transform Diagnosis? FDA Fast-Tracks Review - StockTitan
Could This New Prostate Cancer Treatment Change Patient Outcomes? Miami Trial Now Recruiting - StockTitan
Telix Pharmaceuticals Ltd (TLPPF) (FY 2024) Earnings Call Highlights: Record Revenue Growth and ... By GuruFocus - Investing.com Canada
Can Telix's Triple Product Launch in 2025 Justify Its Bold $1.2B Revenue Target? - StockTitan
Clinical Trial Success: Telix's Revolutionary Prostate Cancer Treatment Shows Promising Results - StockTitan
Major Breakthrough: Revolutionary Prostate Cancer Detection Tool Gets UK Green Light - StockTitan
Telix Pharmaceuticals acquires ImaginAb assets and technology - Investing.com
Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform - GlobeNewswire Inc.
Inside Telix's Strategic $45M ImaginAb Acquisition: Next-Gen Cancer Treatment Pipeline Secured - StockTitan
Telix Pharmaceuticals Acquires RLS USA in Major $230M Radiopharmacy Network Deal - StockTitan
ImaginAb Sells Therapeutic Pipeline to Telix Pharmaceuticals, Focuses on CD8 ImmunoPET Development - StockTitan
Telix Pharmaceuticals CEO to Present at J.P. Morgan Healthcare Conference 2024 - StockTitan
Telix Pharmaceuticals Acquires ImaginAb's Cancer Drug Pipeline in $45M Strategic Deal - StockTitan
ASX December health sector winners… and a 91pc drop for a trial-flopped stock - Stockhead
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
Clayton Utz M&A partner Niro Ananda set to resign; KWM eyed - The Australian Financial Review
Health Check: ASX sleep company emerges from slumber with a revenue and earnings upgrade - Stockhead
UBS bullish on Telix stock—Illuccix growth & therapeutic expansion fuel upside - Investing.com
Key Investors Say Bet on These Stocks at Sohn Australia Conference - BNN Bloomberg
TLXTelix Pharmaceuticals Ltd ADR Latest Stock News & Market Updates - StockTitan
Telix Pharmaceuticals Debuts on Nasdaq Global Select Market Under TLX Symbol - StockTitan
Liverpool Partners, Adamantem seek new owner for Plena Healthcare - The Australian Financial Review
Telix spins off radiopharma unit to form Rhine Pharma | Pharmaceutical | The Pharmaletter - The Pharma Letter
Guess which top 100 ASX stock is venturing off to the Nasdaq - The Motley Fool Australia
Telix Files Form 20-F Registration Statement for Nasdaq ADS - GlobeNewswire
Up 66% in FY24, will Telix Pharmaceuticals shares continue? - The Motley Fool Australia
TLX ASX: Telix pulls $300m Nasdaq IPO as investors demand deep discount - The Australian Financial Review
Radiopharma-focused Telix heats up IPO summer market with $200M offering - Fierce Biotech
Pharmaceutical Industry Mergers & Acquisitions Roundup - Contract Pharma
Australia's Telix Pharmaceuticals jumps on potential US listing - Reuters.com
Check Up: These 4 ASX healthcare stocks come with Strong Buy recommendations - Stockhead
Queen's University Leads Irish Trial of New Prostate Cancer Treatment - Imaging Technology News
Morningstar | Empowering Investor Success - Morningstar
Telix Pharmaceuticals Ltd Adr (TLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.13%
1.23%
자본화:
|
볼륨(24시간):